Hemophilia B
Watchlist
Retrieved
2022-04-26
Source
Trials
—
Genes
F9,
F8,
COX8A,
AK3,
AAVS1,
F2,
F3,
EGF,
ALB,
F5,
SMUG1,
CCHCR1,
EBP,
EIF2AK1,
AMT,
CCRL2,
ST14,
TFPI,
IFI30,
TNFRSF11A,
SACM1L,
FAM72B,
KRT20,
DCXR,
POLE3,
SERHL,
AASDHPPT,
TP53,
RN7SL263P,
NBEAL1
F9,
F8,
COX8A,
AK3,
AAVS1,
F2,
F3,
EGF,
ALB,
F5,
SMUG1,
CCHCR1,
EBP,
EIF2AK1,
AMT,
CCRL2,
ST14,
TFPI,
IFI30,
TNFRSF11A,
SACM1L,
FAM72B,
KRT20,
DCXR,
POLE3,
SERHL,
AASDHPPT,
TP53,
RN7SL263P,
NBEAL1,
RIOX1,
HPS6,
FAM72A,
RIOX2,
VIPR1,
SMN2,
TLR4,
FCGRT,
CCT,
MS4A1,
CD38,
CFTR,
CGA,
CTLA4,
DBP,
EMD,
F11,
FGG,
SPRR2A,
G6PD,
GAD1,
GCY,
HLA-A,
IL10,
KRT31,
MNT,
TNFRSF11B,
SOX3,
H3P11
Drugs
Adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene,
Adeno-associated viral vector containing the human factor IX gene,
Albutrepenonacog alfa
(
IDELVION
)
Adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene,
Adeno-associated viral vector containing the human factor IX gene,
Albutrepenonacog alfa
(
IDELVION
),
Anti-inhibitor coagulant complex
(
FEIBA
),
Antihemophilic factor / Von Willebrand factor complex (human)
(
ALPHANATE,
HUMATE -P
),
Desmopressine acetate
(
DESMOPRESSIN ACETATE AVENTIS BEHRING L.L.C.,
OCTIM,
MINIRIN
),
Eftrenonacog alfa
(
ALPROLIX
),
Fidanacogene elaparvovec,
Fitusiran,
Human coagulation factor IX (antihemophilic B factor)
(
BETAFACT,
ALPHANINE,
NONAFACT
),
Humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor,
Lentiviral vector encoding human coagulation factor IX,
Long acting recombinantFactor VIIa-CTP3,
Marzeptacog alfa (activated),
Moroctocog alpha
(
REFACTO AF
),
Octocog alpha
(
ADVATE,
HELIXATE NEXGEN,
KOGENATE BAYER,
KOVALTRY,
IBLIAS
),
Pegylated recombinant factor VIIa,
Pegylated recombinant human factor IX
(
REFIXIA
),
Recombinant adeno-associated viral vector containing a codon-optimized Padua derivative of human coagulation factor IX cDNA,
Recombinant coagulation factor VIIa (rFVIIa)
(
NOVOSEVEN,
NOVOSEVEN RT
),
Recombinant factor VIIa modified with three terminal repeats derived from the beta chain of human chorionic gonadotropin,
Recombinant fusion protein linking human coagulation factor VIIa with human albumin (rVIIa-FP),
Sequence-modified human recombinant factor VIIa,
Vatreptacog alfa (activated),
nonacog alfa
(
BENEFIX
),
nonacog gamma
(
RIXUBIS
),
recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant,
recombinant human factor IX protein modified with three point mutations
Registered!
Hemophilia B is a bleeding disorder that slows the blood clotting process. People with this disorder experience prolonged bleeding or oozing following an injury or surgery. In severe cases of hemophilia, heavy bleeding occurs after minor injury or even in the absence of injury. Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. Milder forms may not become apparent until abnormal bleeding occurs following surgery or a serious injury. People with an unusual form of hemophilia B, known as hemophilia B Leyden, experience episodes of excessive bleeding in childhood but have few bleeding problems after puberty. Hemophilia B is inherited in an X-linked recessive pattern and is caused by mutations in the F9 gene.[719]